528 related articles for article (PubMed ID: 16223045)
1. [Comparative analysis of life quality in patients receiving beta-blockers and xalathane (latanoprost)].
Tugushi OA; Shliapuzhnikova AV; Listopadova NA
Vestn Oftalmol; 2005; 121(4):41-3. PubMed ID: 16223045
[No Abstract] [Full Text] [Related]
2. Twenty-four hour intraocular pressure reduction with latanoprost compared with pilocarpine as third-line therapy in exfoliation glaucoma.
Konstas AG; Lake S; Maltezos AC; Holmes KT; Stewart WC
Eye (Lond); 2001 Feb; 15(Pt 1):59-62. PubMed ID: 11318297
[TBL] [Abstract][Full Text] [Related]
3. A comparative evaluation of pilocarpine 1% and clonidine 0.125% versus timolol 0.5%.
Sihota R; Agarwal HC; Rajashekar YL
Indian J Ophthalmol; 1996 Jun; 44(2):87-9. PubMed ID: 8916595
[TBL] [Abstract][Full Text] [Related]
4. [Glaucoma].
Funk J
Ther Umsch; 2009 Mar; 66(3):173-81. PubMed ID: 19266464
[TBL] [Abstract][Full Text] [Related]
5. [Prospects of using latanoprost, prostaglandin F2 alpha analog, in hypotensive therapy for glaucoma].
Egorov EA; Nesterov AP; Romanova OV
Vestn Oftalmol; 1998; 114(4):19-20. PubMed ID: 9771080
[TBL] [Abstract][Full Text] [Related]
6. Prepared association of metipranolol 0.1% + pilocarpine 2% and of timolol 0.5% + pilocarpine 2%. Comparison of clinical efficacy and topical tolerability in the treatment of patients affected by POAG tonometrically uncontrolled with beta-blocker alone (two-centre study).
Boles Carenini B; Brogliatti B; Dorigo MT; Vadalà G; Protti R; Bellone A
Acta Ophthalmol Scand Suppl; 1997; (224):54-5. PubMed ID: 9589740
[No Abstract] [Full Text] [Related]
7. [Xalathane: comparative assessment of efficacy and safety in hypotensive therapy of glaucoma].
Erichev VP; Iakubova LV
Vestn Oftalmol; 1998; 114(4):20-1. PubMed ID: 9771081
[TBL] [Abstract][Full Text] [Related]
8. The usefulness of dapiprazole, an alpha-adrenergic blocking agent, in pigmentary glaucoma.
Mastropasqua L; Carpineto P; Ciancaglini M; Gallenga PE
Ophthalmic Surg Lasers; 1996 Sep; 27(9):806-9. PubMed ID: 8878205
[TBL] [Abstract][Full Text] [Related]
9. An uncommon presentation of acute angle closure glaucoma.
Berkoff DJ; Sanchez LD
J Emerg Med; 2005 Jul; 29(1):43-4. PubMed ID: 15961006
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the additive effect of bunazosin on latanoprost in primary open-angle glaucoma.
Maruyama K; Shirato S; Haneda M
Jpn J Ophthalmol; 2005; 49(1):61-2. PubMed ID: 15692779
[No Abstract] [Full Text] [Related]
11. Latanoprost and cholinergic agonists in combination.
Toris CB; Alm A; Camras CB
Surv Ophthalmol; 2002 Aug; 47 Suppl 1():S141-7. PubMed ID: 12204711
[TBL] [Abstract][Full Text] [Related]
12. Latanoprost therapy in patients with glaucoma and ocular hypertension inadequately controlled with carteolol.
Yasar T; Ozdemir M; Andi I; Ozdemir G; Simsek S
Jpn J Ophthalmol; 2004; 48(2):172-3. PubMed ID: 15060799
[No Abstract] [Full Text] [Related]
13. Comparing diurnal and nocturnal effects of brinzolamide and timolol on intraocular pressure in patients receiving latanoprost monotherapy.
Liu JH; Medeiros FA; Slight JR; Weinreb RN
Ophthalmology; 2009 Mar; 116(3):449-54. PubMed ID: 19157559
[TBL] [Abstract][Full Text] [Related]
14. Comparison of ocular hypotensive effect and safety of brinzolamide and timolol added to latanoprost.
Miura K; Ito K; Okawa C; Sugimoto K; Matsunaga K; Uji Y
J Glaucoma; 2008; 17(3):233-7. PubMed ID: 18414111
[TBL] [Abstract][Full Text] [Related]
15. Intraocular pressure, safety and quality of life in glaucoma patients switching to latanoprost from adjunctive and monotherapy treatments.
Haverkamp F; Wuensch S; Fuchs M; Stewart WC
Eur J Ophthalmol; 2004; 14(5):407-15. PubMed ID: 15506603
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of latanoprost versus pilocarpine/timolol maleate fixed combination in patients with primary open-angle glaucoma or ocular hypertension.
Kałuzny J; Sobecki R; Czechowicz-Janicka K; Kecik D; Kałuzny BJ; Stewart JA; Stewart WC
Acta Ophthalmol; 2008 Dec; 86(8):860-5. PubMed ID: 18721251
[TBL] [Abstract][Full Text] [Related]
17. The additive intraocular pressure-lowering effect of latanoprost in combined therapy with other ocular hypotensive agents.
Hoyng PF; Rulo A; Greve E; Watson P; Alm A
Surv Ophthalmol; 1997 Feb; 41 Suppl 2():S93-8. PubMed ID: 9154283
[TBL] [Abstract][Full Text] [Related]
18. Circadian intraocular pressure control with dorzolamide versus timolol maleate add-on treatments in primary open-angle glaucoma patients using latanoprost.
Tamer C; Oksüz H
Ophthalmic Res; 2007; 39(1):24-31. PubMed ID: 17164574
[TBL] [Abstract][Full Text] [Related]
19. The role of the uveoscleral outflow in the management of pigmentary glaucoma: a 24-month study comparing latanoprost with timolol.
Carpineto P; Ciancaglini M; Zuppardi E; Doronzo E; Mastropasqua L
Acta Ophthalmol Scand Suppl; 2000; (232):54. PubMed ID: 11235538
[No Abstract] [Full Text] [Related]
20. Additive effect of dorzolamide or carteolol to latanoprost in primary open-angle glaucoma: a prospective randomized crossover trial.
Maruyama K; Shirato S
J Glaucoma; 2006 Aug; 15(4):341-5. PubMed ID: 16865013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
